BROOKLINE CAPITAL ACQUISITIO (BCAC)

US11374E1047 - Common Stock

22.71  +12.63 (+125.3%)

After market: 16.11 -6.6 (-29.06%)

News Image
2 years ago - Moore Kuehn, PLLC

Moore Kuehn Encourages VCKA, RNER, BCAC, and SUMR Investors to Contact Law Firm

/PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential...

News Image
5 years ago - TalkMarkets

Week In Review: Nanjing's NJCTTQ Agrees To $4 Billion Package For Abpro Bi-Specific Immunotherapies

NJCTTQ, a Nanjing biopharma, announced a deal worth up to $4 billion to co-develop bispecific immunotherapies discovered by Abpro of Massachusetts.